Google NewsWhy Did Genetic Signatures (ASX:GSS) Report Lower Cash Outflow in Its September 2026 Quarter? - Kalkine
Why Did Genetic Signatures (ASX:GSS) Report Lower Cash Outflow in Its September 2026 Quarter? Kalkine
GSS
Pharmaceuticals, Biotechnology & Life Sciences
Genetic Signatures
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 11 June 2026
- Reported shorts
- 7K
- Shares on issue
- 227.139M
Genetic Signatures (GSS) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXQuarterly Activities/Appendix 4C Cash Flow Report
other announcement
Notice of Extraordinary General Meeting
other announcement
Genetic Signatures and Microba agree to all-scrip merger to create $51m diagnostics group
Sydney-based molecular diagnostics company Genetic Signatures (ASX: GSS) has announced plans to merge with Brisbane gut health specialist Microba Life Sciences (ASX: MAP) in an all-scrip deal that will create a $51 million diagnostics group. Under the terms of the agreement announced today, Microba shareholders wil...
StockheadHealth Check: Microba and Genetic Signatures have urge to merge, but is it game over?
Diagnostic houses Microba and Genetic Signatures have announced a scheme of arrangement that could leave 18% Genetic holder BCAL in ... Read More The post Health Check: Microba and Genetic Signatures have urge to merge, but is it game over? appeared first on Stockhead.
GSS Investor Presentation - Proposed Merger with MAP
takeover announcement
GSS and MAP agree to Commercial Terms for Merger
takeover announcement
Receipt of Section 249D Notice from BCAL Diagnostics
other announcement
Date of AGM and Closing Date for Director Nominations
other announcement
KalkineWhy Is a Board Battle Brewing at Genetic Signatures?
Highlights Genetic Signatures (ASX:GSS) faces a board challenge from BCAL Diagnostics (ASX:BDX), seeking removal of its chairman A dispute has emerged over the reported nature of BCAL's increased shareholding in the company Broker Canaccord has flagged several healthcare names likely for re-rating, spanning Telix Pharmaceuticals, CogState and Avita Medical Genetic Signatures (ASX:GSS) finds itself at the centre of a genuine board battle, with rival BCAL Diagnostics (ASX:BDX) pushing for the re...
Health Check: Board tussle looms at takeover target Genetic Signatures
BCAL Diagnostics is seeking to remove the chairman of its potential takeover quarry Genetic Signatures and appoint its old CEO ... Read More The post Health Check: Board tussle looms at takeover target Genetic Signatures appeared first on Stockhead.
Genetic Signatures (ASX:GSS): Board Challenge Emerges Amid Shareholding Queries - Kalkine
Genetic Signatures (ASX:GSS): Board Challenge Emerges Amid Shareholding Queries Kalkine
BDX Holdings of GSS Shares and receipt of Section 249D
other announcement
Genetic Signatures (ASX: GSS) Advances 15.63%: Can the FY26 Reset Rebuild Investor Confidence? - Kalkine
Genetic Signatures (ASX: GSS) Advances 15.63%: Can the FY26 Reset Rebuild Investor Confidence? Kalkine
Investors Watch Genetic Signatures (ASX:GSS) as Merger Talks Highlight Scale and Market Expansion Plans - Kalkine
Investors Watch Genetic Signatures (ASX:GSS) as Merger Talks Highlight Scale and Market Expansion Plans Kalkine
Health Check: Genetic Signatures and Microba talk merger as BCAL crashes the romance
Genetic Signatures and Microba are discussing a merger to create an ASX leader in gastrointestinal conditions. But BCAL watches on. ... Read More The post Health Check: Genetic Signatures and Microba talk merger as BCAL crashes the romance appeared first on Stockhead.
Genetic Signatures and Microba in Merger Discussions
takeover announcement
FY26 Appendix 4G and Corporate Governance Statement
other announcement
FY 26 Annual Results and Investor Webinar Notification
other announcement
Commercial Testing Commences at Hvidovre Hospital in Denmark
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Genetic Signatures (ASX: GSS) Bounces 8% But Remains a Major Loser Over the Year: Is the Molecular Diagnostics Company Near a Floor? - Kalkine
Genetic Signatures (ASX: GSS) Bounces 8% But Remains a Major Loser Over the Year: Is the Molecular Diagnostics Company Near a Floor? Kalkine
GSS Appoints Anne Lockwood as Interim Managing Director
other announcement